The feasibility and efficacy of a novel immunomagnetic ex vivo negative purging method was evaluated on peripheral blood progenitor cells (PBPC) from 13 non-Hodgkin's lymphoma patients (eight follicular, FL; three mantle cell, MCL; two FL with histologic transformation). A peculiar feature of the study was the collection of PBPC after prolonged tumor debulking. Our method included a stem cell enrichment phase followed by cell incubation with anti-B cell MoAbs (anti-CD19, CD20, CD22, CD23), addition of immunobeads, and then positive cell removal by passage on a Max-Sep (Baxter Immunotherapy) cell separator. Engraftment was rapid and stable. Hematological values were assessed 1 and 2 years after the autograft. Purging efficacy was molecularly assessed in a panel of 11 patients who showed persistence of PCR-detectable lymphoma cells on PBPC harvests despite intensified chemotherapeutic debulking. PCR-negativity was obtained in vitro and persisted in vivo after autograft in three FL patients; five more FL patients, whose purged PBPC were PCR+, converted to stable (3 patients) or fluctuating (two patients) PCR negativity after autograft. MCL patients never reached PCR negativity. Thus, ex vivo purging may have a role for FL patients harvesting PCR-positive PBPC after intensified chemotherapy. In contrast, the addition of ex vivo purging seems to be of little if any benefit for MCL patients.
Introduction
In recent years evidence has been provided that young patients with advanced indolent lymphoma may benefit from treatment aimed at maximal tumor reduction and possibly cure, rather than mere disease control. 1, 2 This aggressive approach has been pioneered by researchers at Dana Farber Cancer Institute, who firstly reported clinical and even molecular remissions in follicular lymphoma (FL) patients, using high-dose chemoradiotherapy followed by autograft with ex vivo purged bone marrow (BM) cells. [3] [4] [5] Moreover, the same group showed that infusions of PCR-negative BM grafts were associated with improved disease-free survival. 4 These findings suggest that the use of grafts devoid of residual tumor cells is a basic step towards the eradication of the neoplastic clone.
The use of mobilized peripheral blood progenitor cells has dramatically reduced the toxicity of autograft procedures, allowing a wider application of high-dose chemotherapy with autograft. [6] [7] [8] [9] [10] [11] [12] [13] A high-dose sequential (HDS) chemotherapy regimen followed by PBPC autograft has recently been proposed as an effective treatment for diffuse large-cell lymphoma. 14 In order to adapt this approach to neoplasms with high incidence of bone marrow involvement such as FL and mantle-cell lymphoma (MCL) the protocol was modified, by intensifying tumor debulking and by postponing PBPC collection in order to exploit chemotherapy-based in vivo purging. 13, 15 This modified HDS approach proved effective, since PCR-negative PBPC collections, along with durable post-graft molecular remissions were observed in approximately 65% of FL patients. 16, 17 Notwithstanding this highly intensified approach, about 35% of patients still harvest PCR-positive PBPC collections. 16, 17 In these patients additional treatments are probably required in order to reduce tumor contamination and possibly achieve PCR-negativity. Antibody-mediated ex vivo purging with negative selection proved feasible and often successful in providing PCR-negative grafts when BM is employed as stem cell source. 4, 18 However, it is presently unknown if this procedure is equally effective for mobilized PBPC harvests. 19, 20 The large number of mature myelomonocytic cells in leukapheresis products may represent a major obstacle for effective purging of contaminated harvests. 21 To overcome this problem we designed a novel two-step purging procedure specifically tailored for ex vivo manipulation of PBPC. During the first step, apheresis products are spun over a low-density Ficoll/metrizoate gradient in order to reduce overall cellularity. 21 During the second step, enriched PBPC collections undergo immunologic negative separation.
In the present study, this strategy has been used to purge PBPC harvests obtained from a panel of 11 patients whose collections were PCR-positive at the end of our 'modified HDS' regimen. Two more patients with a particularly aggressive disease (transformed FL) in which a molecular marker was not available were also included in the study. A purging procedure based on immunologic negative selection was chosen. Aims of the study were: (1) to evaluate whether negative ex vivo purging of PBPC is feasible and reproducible in terms of progenitor cell recovery, short-term engraftment and longterm hematopoietic reconstitution; (2) to evaluate if this procedure is able to increase the number of patients undergoing transplantation with PCR negative grafts; and (3) to evaluate if the infusion of purged grafts is associated with persistent PCR-negativity after transplantation.
Patients and methods

Patients, treatment plan and response criteria
Thirteen patients with advanced-stage non-Hodgkin's lymphoma (NHL) received a modified high-dose sequential (HDS) chemotherapy program as front-line treatment. This treatment included a final autograft with ex vivo purged peripheral blood progenitor cells (PBPC). The local Ethical Committee approved the whole program, including the 'in vitro' processing, and all patients gave written informed consent to the whole procedure. Histopathologic diagnosis of NHL was available for all patients. The diagnosis of FL and MCL was based on morphologic and immunophenotypic criteria. Eligibility criteria have been reported elsewhere. 13, 16 Main patient characteristics are shown in Table 1 .
The 'modified HDS' is a further intensification of the original HDS, developed a few years ago by the Milan Cancer Center and successfully used in diffuse large-cell NHL. 7, 14 This regimen has already been described. 13, 15 Main differences between the original and the modified HDS are the introduction of two APO and two DHAP courses before the HDS phase, and the postponing of PBPC collections after the completion of the last high-dose chemotherapy course with the introduction of a 4-week chemotherapy-free interval before the mobilizing phase in order to allow an adequate marrow recovery prior to PBPC collection. 15 Clinical response was assessed by full restaging before autograft, 2 months after autograft and thereafter at 3-month intervals for the first year and at 6-month intervals for the subsequent years. Clinical response was assessed using standard criteria. 13, 14 
Collection and evaluation of hemopoietic progenitors
Cell blood counts and number of circulating CD34+ve cells were monitored daily starting from day +9 following highdose cyclophosphamide to predict the number and timing of leukaphereses, according to previously published procedures. [21] [22] [23] Leukaphereses were performed using continuous-flow blood cell separators (Cobe Spectra Apheresis Sys- CD34+ve cells and CFU-GM were quantified before in vitro manipulation, after progenitor cell enrichment and after monoclonal antibody (MoAb)-mediated purging. The in vitro colony-forming assay was performed by plating in semisolidmedium 1, 10 and 100 l of the cell suspension, without any additional cell separation, as described elsewhere. 24 This excluded any progenitor cell enrichment due to cell separation. Culture conditions have been previously described. 23, 24 Colonies were scored after 14 days of incubation and the mean CFU-GM value per ml of cell suspension was calculated. The total amount of CD34+ve cells (×10 CD34+ve cells/kg were considered as the minimal required dose of harvested progenitors for patients to be autografted with PBPC only. In two patients in whom sub-optimal amounts of progenitors were harvested, additional 'in vitro' purged marrow cells were employed.
Progenitor cell enrichment
Prior to negative selection, leukapheresis products were processed in order to reduce overall cellularity, by removing mature myelomonocytic cells. For this purpose we developed an in vitro cell separation procedure based on the use of Ficoll/metrizoate gradient at low density (1067 g/l), as detailed elsewhere. 21 Following this single step density gradient separation, cells were resuspended in IMDM supplemented with 10% autologous plasma + 1% human serum albumin and adhered for 1 h. Adherent cells were then removed.
MoAb-mediated purging of PBPC
Nucleated cells were then incubated with a cocktail of anti-B cell monoclonal antibodies (MoAb), ie anti-CD19, anti-CD20, anti-CD22 and anti-CD23 (kindly supplied by Baxter Immunotherapy, Deerfield, IL, USA), at 4°C for 30 min. Immunobeads (Dynabeads; Baxter Immunotherapy) were then added at a beads to cell ratio of 2:1 and the incubation was prolonged at 4°C for 30 min with gentle shaking. Incubation was performed in the presence of 5 mg/ml human immunoglobulins in order to reduce non-specific binding of immunobeads to monocytes. Cells were then processed on a Max-Sep cell separator (Baxter Immunotherapy), at a 20 ml/min flow rate, in order to remove immunobead-coated B cells. 25 Immunobead incubation and cell separation were repeated twice.
Nucleic acid extraction
BM, PB and lymph node samples were collected during standard diagnostic procedures. Genomic DNA was purified by proteinase K digestion, phenol/chloroform extraction and ethanol precipitation. 16 ,26
Molecular analysis
The presence of minimal residual disease (MRD) was investigated by PCR analysis before and after purging procedures. PCR status after autograft has been monitored at 6-12 month intervals until CR was maintained. In FL patients, we employed the Bcl-2/lgH translocation as tumor marker while in MCL either the Bcl-1/lgH translocation or the lgH rearrangement was used. PCR amplification of tumor markers was performed as follows:
Amplifications of major (MBR) and minor (mcr) breakpoints were performed using nested PCR. The oligonucleotide primers were the same originally designed by Gribben et al. 4, 5, 27, 28 Briefly, 1 g of genomic DNA was amplified in 200 M dNTPs, 1 × Taq buffer (50 mM KCl, 10 mM Tris-HCl pH 8, 2 mM MgCl 2 , 0.1% (wt/vol) gelatin) final concentration, adding 2.5 units of Taq DNA polymerase (Promega, Madison, WI, USA) in a final volume of 50 l. The amplification was performed as follows: 94°C for 1 min; 55°C (MBR) or 58°C (mcr) for 1 min; 72°C for 1 min; 25 cycles, followed by a 7 min final extension at 72°C. Five l of the first reaction were reamplified for 30 cycles using internal primers. PCR products were then analyzed by electrophoresis on 2% agarose gels. Polyclonal DNAs were used as negative controls.
(b) Bcl-1/lgH translocations:
Amplification of the Bcl-1/JH junction was performed using semi-nested PCR. 29 A consensus primer derived from 3Ј end of JH region JH3: 5Ј-ACCTGAGGAGACGGTGACC-3Ј was used for chromosome 14. The chromosome 11q13-specific oligonucleotides had the following sequences: P2: 5Ј-GAAGGACTTGTGGGTTGC-3Ј; P4: 5Ј-GCTGCTGTACACATCGGT-3Ј. For PCR amplification, 1 g of genomic DNA was amplified with P2 and JH3 primers (10 picomols) in 200 M dNTPs, 1× Taq buffer (50 mM KCl, 10 mM Tris-HCl pH 8, 1.5 mM MgCl 2 0.1% (wt/vol) gelatin) final concentration, adding 2.5 units Taq DNA polymerase (Promega) in a final volume of 50 l. First amplification was performed as follows: 94°C for 1 min; 58°C for 30 s; 72°C for 30 s; 33 cycles, followed by a 7 min final extension at 72°C. Two l of the first PCR product were then reamplified with an internal primer P4 and JH3 (10 picomols) in the same conditions as above. Amplified DNAs were analyzed by electrophoresis on 2% agarose gels. Polyclonal DNAs were used as negative controls. 26 Sequence analysis was performed using the PC-GENE software (IntelliGenetics, Mountain View, CA, USA) in order to identify the third complementarity-determining region. From this hypervariable portion of the IgH rearrangement a tumor specific probe suitable for MRD analysis was designed. 26, 31 DNA samples derived from pre-and post-purging PBPC and BM cells, as well as BM samples obtained after autograft were then evaluated for the presence of residual tumor cells as previously described. 16 Briefly, 1 g of genomic DNA was amplified according to the same conditions used for diagnostic DNA. PCR products were then analyzed by agarose gel electrophoresis, blotted overnight, and hybridized to CDR3 probes end-labeled with ␥-32 P-ATP. To avoid false negatives, all DNA samples failing to produce a PCR product were amplified twice, and the DNA quality was checked by amplifying the sequence of p53 exon 5 or N-ras exon 2.
Results
Recovery of progenitor cells after ex vivo purging
A total of 30 procedures on leukapheresis products from 13 patients were performed. Median number of leukaphereses for each patient was two (range 2-4). Total cellularity, CFU-GM/kg and CD34 + cells/kg were evaluated before ex vivo manipulation, after progenitor cell enrichment and after immunomediated purging. As shown in Table 2 , progenitor cell enrichment procedures allowed a median reduction to 14% of the starting cellularity, with a median CFU-GM and CD34
+ cells recovery of 62% and 74%, respectively. Immunomediated purging did not significantly decrease CFU-GM and CD34 + cell recovery.
Short-term engraftment and long-term hematopoietic reconstitution
The median number of grafted progenitors was 78 × 10 4 CFU-GM/kg (range 24-129) and 7.4 × 10 6 CD34 + cells/kg (range 3.2-13.9). Two patients had a final recovery of less than 30 × 10 4 CFU-GM/kg and less than 5 × 10 6 CD34+ve cells/kg and were autografted with both purged PBPC and BM cell; the remaining 11 patients were autografted with PBPC alone. Short-term engraftment was rapid. Neutrophil counts greater than 500/l and platelet values greater than 50 000 were reached after a median time of 12 (range 10-16) and 15 (range 12-20) days, respectively. Median number of platelet transfusions during the aplastic phase was two (range 1-4). Shortterm engraftment was similar to that observed using unmanipulated PBPC. 32 As shown in Table 3 , long-term engraftment was durable with most of evaluable patients displaying normal blood cell counts at one and two years since autograft. One single patient (N357) who initially showed normal short-term hematopoietic engraftment experienced the onset of long lasting asymptomatic thrombocytopenia after delivery of extensive post-transplant abdominal radiotherapy as a consolidation treatment. This patient is still in CR with platelet values ranging between 30 and 60 000/mm 3 .
Molecular analysis of PBPC and BM harvests before and after ex vivo purging
At the time of PBPC collections all patients were in CR except a FL who had limited disease persistence at BM level (N281). Eleven patients had a molecular marker and were evaluable for MRD analysis. The bcl-2 rearrangement was used in eight FL patients, whereas the bcl-1 rearrangement (one patient) or the IgH rearrangement was used in the three MCL patients. All three methods employed for MRD analysis can routinely detect one clonal cell in a background of 100 000 normal cells. 4, 16, 29, 31 As shown in Table 4 , persistence of PCR-detectable lymphoma cells was observed in 11 out of 11 PBPC collections before in vitro manipulation. Ex vivo purging of PBPC collections succeeded in eradicating molecularly detectable MRD in three out of eight FL patients (37.5%) and none of MCL patients. Two patients (N347 and N281) were autografted with both PBPC and BM purged cells. In both patients purged BM harvests were PCR negative.
Table 3
Cell blood counts at 1 and 2 years after purged-PBPC autograft 
Molecular follow-up after autologous transplantation with ex vivo purged PBPC collections
Results of MRD analysis of BM samples obtained after autograft are reported in Figure 1 and Table 4 . FL patients (case N427, N347 and N357) who received PCR-negative PBPC grafts showed persistent PCR negativity of BM follow-up samples following autograft. Three more FL patients (case N281, N360, N185) were repeatedly PCR negative after transplantation, despite the infusion of PCR-positive PBPC collections. These six patients who achieved a stable PCR-negative status are still alive and in persistent CR, at a median followup of 38 months (range 19-53). The remaining FL patients (case N234, N428) autografted with PCR positive PBPC collections had fluctuating negative/positive PCR results after transplantation. These patients eventually relapsed at 31 and 38 months from transplantation. None of the three MCL patients (case N140, N637 and N538) achieved PCR negativity either after in vitro purging or after transplantation. As shown in Figure 1 , all MCL patients relapsed at 10, 15 and 27 months from transplantation; one of them (case N538) died from progressive disease 12 months after transplantation.
Discussion
In the present study we developed a novel two-step purging procedure specifically designed for MoAb-mediated purging of PBPC. Our method has been assessed on 13 patients and proved feasible and reproducible. Recovery was satisfactory both in terms of CD34 + cells and CFU-GM. Engraftment was fast and durable for all hematopoietic lineages. MRD analysis has been performed in eight FL and three MCL patients who had an available molecular marker and showed PCR-detectable disease on pre-purging PBPC harvests. Our approach allowed eradication of molecularly detectable tumor cells from both purged PBPC and post-graft samples in three FL patients; three additional FL patients achieved a PCR-negative status after transplantation despite the infusion of post-purging PCR-positive PBPC collections. In contrast, our procedure constantly failed to eradicate MRD in patients with MCL. Interestingly, we observed that relapse occurred only in those patients who were PCR-positive after transplantation, while patients achieving a post-graft PCR-negative status are still in persistent clinical and molecular remission.
PBPC harvests have always been considered as difficult progenitor cell sources for MoAb-mediated negative selection procedures, mostly because they require manipulation of a large number of cells. 19, 20 For this reason, positive selection methods have been preferred by most centers in this setting. [33] [34] [35] [36] However, there are some concerns regarding the use of CD34 + positive selection: first, binding and detachment of murine MoAbs and magnetic beads may potentially damage progenitor cells. Second, it has been demonstrated that at least a subset of immature tumor cells may coexpress CD34 and CD19. 37 Finally, the complete depletion of T and NK cells can be detrimental to post-graft immunologic reconstitution. 38 By contrast, our procedure, allowed satisfactory recovery of CD34 + cells, without affecting cell populations which are highly relevant for hematopoietic and immunologic reconstitution.
Hematopoietic reconstitution efficiency has been assessed both short-and long-term. Our study demonstrated that purged PBPC do take rapidly and efficiently. Thus, even after 'ex vivo' manipulation, PBPC should still be preferred to BM Table 4 Evaluation of minimal residual disease before and after ex vivo purging
Patient number
Molecular marker PCR test before purging PCR test after purging cells, due to shorter neutropenic phase and reduced mortality and morbidity risk, as already reported by other groups using either negative or positive cell selection. [39] [40] [41] Moreover, in spite of prolonged and intensive treatment, enough PBPC could be collected in most patients, with few leukaphereses. Two main reasons can explain this result: first, our modified HDS program allows adequate release of CD34 + cells by introducing a chemotherapy-free interval before the mobilizing regimen, 15, 42 second, our two-step purging procedure has an acceptable aspecific loss of CD34 + cells following ex vivo manipulation.
Purged PBPC allowed also a successful long-term engraftment in the vast majority of patients. This is remarkable since PBPC collections were obtained at the end of a particularly intense chemotherapy treatment, underwent a complex 'ex vivo' procedure and were used as support for a conditioning regimen (mitoxantrone 60 mg/m 2 + melphalan 180 mg/m 2 ) which is considered relatively intense and probably even more myelotoxic than several other widely used regimens such as the BEAM protocol. 32 In contrast, it is not presently known to what extent other purging approaches, particularly positive selection of CD34 + cells, could affect long-term hematopoietic reconstitution.
Our method allowed the infusion of PCR-negative PBPC grafts in a significant proportion of FL patients, but proved unsuccessful in eradicating MRD in three patients with MCL. This is not surprising, since similar results were obtained at Dana Farber Cancer Institute using BM cells and complementmediated lysis. 29 This can be explained by the presence of a higher tumor burden in PBPC from MCL patients or alternatively by a peculiar resistance of MCL cells to antibodymediated selection. Whichever the explanation, our results indicate that even a very intensive chemotherapy approach combined with ex vivo purging is unable to eradicate the molecularly detectable malignant clone in this neoplasm.
The rate of PCR negative detection following ex vivo purging in our panel of FL patients is somehow lower than observed by Gribben et al 4 using BM cells and complementmediated lysis (37% vs 50%). However we believe that a comparison between these two procedures is difficult if not impossible because of remarkable differences between patient populations. Researchers at Dana Farber Cancer Institute performed in vitro purging after minimal or conventional treatment on an unselected population of FL patients. Our study, on the other hand, focused on a highly selected population of patients which were unable to harvest PCR-negative PBPC collections, despite a highly intensified chemotherapy regimen which successfully eradicated MRD in the majority of patients. It is reasonable to think that these two populations may differ in terms of tumor burden, antigen expression, or other potential mechanisms of tumor cell resistance to antibody-mediated selection. Nevertheless, the successful clearance of PCR-detectable disease obtained in a fraction of our FL patients is remarkable, if one considers that the ex vivo procedure was applied to a patient population displaying a MRD particularly resistant to intensified chemotherapy. This points towards a complementary role of 'in vivo' and 'ex vivo' purging approaches in order to achieve a PCR-negative status in the highest fraction of FL patients.
Three patients achieved a PCR-negative status despite the infusion of purged grafts containing PCR-detectable disease. This is surprising since we observed similar results only in one of 15 comparable FL patients who received the HDS program and were autografted in CR with unmanipulated PCR positive PBPC (data not shown). These results are consistent with persistence of PCR-detectable tumor cells with an impaired clonogenic potential in the purged PBPC graft. An alternative explanation is that infused tumor cells are too few to be successfully detected after transplantation. However, since these patients experience a prolonged clinical and molecular remission, it is reasonable to think that this small number of viable tumor cells is not sufficient to sustain a disease recurrence and thus is clinically not relevant.
In conclusion, our study shows that inclusion of ex vivo negative purging in a high-dose chemotherapy program may have a distinct role in the treatment strategy for FL, by increasing the proportion of patients achieving a durable PCR negativity and long-term clinical remission. By contrast both HDS chemotherapy and 'ex vivo' purging methods are unable to induce long-lasting molecular and clinical remissions in MCL patients and innovative approaches, such as 'in vivo' infusions of anti-B cell monoclonal antibodies, or alternatively, allogenic bone marrow transplantation are probably required. 29, 43, 44 
